Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2868766/0/en/Cullinan-Therapeutics-to-Present-Clinical-Data-from-Phase-1-Study-Evaluating-Novel-Anti-MICA-B-Antibody-CLN-619-as-Monotherapy-and-in-Combination-with-a-Checkpoint-Inhibitor-in-Pat.html

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.